In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA ...
Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...
Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate ...
Number 5: Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term comparable efficacy and safety up to week 52. Number 4: The FDA approved ...
Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in patients with neovascular age-related macular degeneration (nAMD). Enzeevu ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback